Regadenoson: Difference between revisions
Kiran Singh (talk | contribs) No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
{{Drugbox | {{Drugbox | ||
| Verifiedfields = changed | | Verifiedfields = changed | ||
| Line 51: | Line 50: | ||
| synonyms = 1-[6-amino-9-[(2''R'',3''R'',4''S'',5''R'')-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]purin-2-yl]- ''N''-methylpyrazole-4-carboxamide | | synonyms = 1-[6-amino-9-[(2''R'',3''R'',4''S'',5''R'')-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]purin-2-yl]- ''N''-methylpyrazole-4-carboxamide | ||
}} | }} | ||
__NOTOC__ | |||
{{SI}} | {{SI}} | ||
{{CMG}} | {{CMG}} | ||
==Overview== | ==Overview== | ||
'''Regadenoson''' ([[International Nonproprietary Name|INN]], code named '''CVT-3146''') is an [[Adenosine A2a receptor|A<sub>2A</sub>]] [[adenosine receptor]] [[agonist]] that is a coronary [[vasodilator]]. It produces maximal [[hyperemia]] quickly and maintains it for an optimal duration that is practical for radionuclide [[myocardial perfusion imaging]].<ref name="pmid15261132">{{cite journal |author=Cerqueira MD |title=The future of pharmacologic stress: selective A2A adenosine receptor agonists |journal=Am. J. Cardiol. |volume=94 |issue=2A |pages=33D–40D; discussion 40D–42D |year=2004 |month=July |pmid=15261132 |doi=10.1016/j.amjcard.2004.04.017 |url=http://linkinghub.elsevier.com/retrieve/pii/S0002914904005934}}</ref> | '''Regadenoson''' ([[International Nonproprietary Name|INN]], code named '''CVT-3146''') is an [[Adenosine A2a receptor|A<sub>2A</sub>]] [[adenosine receptor]] [[agonist]] that is a coronary [[vasodilator]]. It produces maximal [[hyperemia]] quickly and maintains it for an optimal duration that is practical for radionuclide [[myocardial perfusion imaging]].<ref name="pmid15261132">{{cite journal |author=Cerqueira MD |title=The future of pharmacologic stress: selective A2A adenosine receptor agonists |journal=Am. J. Cardiol. |volume=94 |issue=2A |pages=33D–40D; discussion 40D–42D |year=2004 |month=July |pmid=15261132 |doi=10.1016/j.amjcard.2004.04.017 |url=http://linkinghub.elsevier.com/retrieve/pii/S0002914904005934}}</ref> | ||
| Line 62: | Line 63: | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category:Vasodilators]] | [[Category:Vasodilators]] | ||
[[Category:Cardiovascular Drugs]] | [[Category:Cardiovascular Drugs]] | ||
[[Category:Drug]] | [[Category:Drug]] | ||
Revision as of 21:52, 23 July 2014
{{Drugbox | Verifiedfields = changed | verifiedrevid = 413312613 | IUPAC_name = 2-{4-[(methylamino)carbonyl]- 1H-pyrazol-1-yl}adenosine | image = Regadenoson2.png | width = 300
| tradename = | Drugs.com = Multum Consumer Information | licence_US = Regadenoson | pregnancy_AU = | pregnancy_US = C | pregnancy_category = | legal_AU = | legal_CA = | legal_UK = | legal_US = Rx-only | legal_status = | routes_of_administration = Intravenous
| bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion =
| CAS_number_Ref = 
| CAS_number = 313348-27-5
| CAS_supplemental = 875148-45-1
| ATC_prefix = C01
| ATC_suffix = EB21
| ATC_supplemental =
| PubChem = 219024
| DrugBank_Ref =
| DrugBank =
| UNII_Ref = 
| UNII = 7AXV542LZ4
| KEGG_Ref =
| KEGG = D05711
| ChEMBL_Ref =
| ChEMBL = 1201750
| chemical_formula = | C=15 | H=18 | N=8 | O=5 | molecular_weight = 390.354 g/mol | synonyms = 1-[6-amino-9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]purin-2-yl]- N-methylpyrazole-4-carboxamide }}
|
WikiDoc Resources for Regadenoson |
|
Articles |
|---|
|
Most recent articles on Regadenoson Most cited articles on Regadenoson |
|
Media |
|
Powerpoint slides on Regadenoson |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Regadenoson at Clinical Trials.gov Clinical Trials on Regadenoson at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Regadenoson
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Regadenoson Discussion groups on Regadenoson Patient Handouts on Regadenoson Directions to Hospitals Treating Regadenoson Risk calculators and risk factors for Regadenoson
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Regadenoson |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Regadenoson (INN, code named CVT-3146) is an A2A adenosine receptor agonist that is a coronary vasodilator. It produces maximal hyperemia quickly and maintains it for an optimal duration that is practical for radionuclide myocardial perfusion imaging.[1]
It was approved by the United States Food and Drug Administration on April 10, 2008 and is marketed by Astellas Pharma under the tradename Lexiscan.[2] It has now gained approval in the European Union and is being sold under the name of Rapiscan. It is currently being marketed by GE Healthcare and is being sold in both the United Kingdom and Germany.
Regadenoson has a 2- to 3-minute biological half-life, as compared with adenosine's 30-second half-life. Regadenoson stress protocols using a single bolus have been developed, obviating the need for an intravenous line. Regadenoson stress tests are not affected by the presence of beta blockers, as regadenoson vasodilates but does not stimulate beta adrenergic receptors.[citation needed]
References
- ↑ Cerqueira MD (2004). "The future of pharmacologic stress: selective A2A adenosine receptor agonists". Am. J. Cardiol. 94 (2A): 33D–40D, discussion 40D–42D. doi:10.1016/j.amjcard.2004.04.017. PMID 15261132. Unknown parameter
|month=ignored (help) - ↑ CV Therapeutics and Astellas Announce FDA Approval for Lexiscan(TM)
- Pages with citations using unsupported parameters
- Template:drugs.com link with non-standard subpage
- Articles with changed FDA identifier
- Articles with changed EBI identifier
- All articles with unsourced statements
- Articles with unsourced statements from December 2008
- Articles with invalid date parameter in template
- Vasodilators
- Cardiovascular Drugs
- Drug